Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective of this dose-ranging trial is to assess the efficacy and safety of BAY 59-7939 5 mg – 40 mg once daily dosing in prevention of VTE in men and in postmenopausal women aged 18 years or above undergoing elective primary total hip replacement.
Critère d'inclusion
- Deep Venous Thrombosis prophylaxis